# Immuneering Corporation (IMRX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $4.82, market value $312 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Immuneering Corporation reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 1.6×**. The shares trade at 1.6× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -18.3%** (5-yr avg -34.4%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -25.6%**. Return on equity is negative because earnings are negative.
- **Return on assets: -23.0%**. Each dollar of assets produces -23.0% of profit.

## Growth
- **EPS growth (1 yr): 37.7%**. Earnings per share rose 37.7%.

## Financial health
- **Current ratio: 17.50** (quick 17.50). Current assets cover the next year's liabilities 17.50 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Immuneering Corporation does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (6 analysts). 6 analysts cover Immuneering Corporation; the consensus is strong_buy, with an average price target of $17.17 (+256% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -11.7%** (YTD -26.7%, 3-mo 12.9%). The shares are down 11.7% over twelve months including dividends.
- **From 52-week high: -52.2%** (24.9% above the low). Trading 52% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 0.98** (volatility 89%). Beta of 0.98 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IMRX · Page: https://foliofundamentals.com/stocks/imrx

Not investment advice.